Core Viewpoint - The research presents a novel tumor-targeting nanoplatform that enhances the efficacy of the chemotherapy drug Docetaxel through a combination of photothermal and photodynamic therapy, inducing ferroptosis and promoting a robust anti-tumor immune response [2][6]. Group 1 - The study developed a biocompatible polymer PPEGMA-b-PFMMA (PF) for co-encapsulating Docetaxel and the photosensitizer IR808, forming photothermal-responsive nanoparticles (P8D NP) [4]. - P8D NP utilizes hydrogen peroxide (H₂O₂) in the tumor microenvironment to trigger drug release, significantly improving the solubility and tumor-specific accumulation of both drugs [4]. - Under near-infrared (NIR) laser irradiation, P8D NP generates heat and reactive oxygen species (ROS), facilitating the disintegration of nanoparticles and drug release [4]. Group 2 - Mechanistically, Docetaxel induces the translocation of HMGB1 from the nucleus to the cytoplasm, while photothermal/photodynamic therapy promotes the release of damage-associated molecular patterns (DAMP) and tumor-associated antigens [6]. - These actions enhance the maturation of dendritic cells (DC), antigen presentation, and infiltration of cytotoxic CD8⁺ T cells into the tumor, effectively reversing the immunosuppressive tumor microenvironment [6]. - The combined treatment strategy not only inhibits the growth of distant tumors but also establishes long-term anti-tumor immune memory, preventing tumor recurrence [6].

Core Viewpoint - The article discusses the promising potential of PD-1 and PD-L1 blockade in cancer treatment, particularly highlighting the challenges faced in treating mismatch repair proficient (pMMR) colorectal cancer (CRC), which constitutes over 95% of CRC patients and is characterized as "cold tumors" that do not respond to PD-1/PD-L1 therapies due to immune suppression in the tumor microenvironment [3][4]. Group 1 - The combination of molecular targeted approaches to release damage-associated molecular patterns (DAMPs) with immune checkpoint inhibitors (ICIs) shows good prospects for treating pMMR CRC [4]. - A novel peptide-grafted polymer-based nanorobot has been developed that can block PD-1/PD-L1 while simultaneously inducing immunogenic cell death (ICD) by disrupting cancer cell membranes, thereby enhancing T cell infiltration [5][7]. - This nanorobot exhibits high specificity by targeting PD-L1 overexpressing cancer cells, ensuring prolonged retention in tumors (> 120 hours) and activating T cell responses against the tumor [7][8]. Group 2 - The nanorobot not only transforms "cold tumors" into "hot tumors" by releasing the inhibition on immune cells but also actively generates inflammatory signals to recruit immune cells, achieving a synergistic effect that enhances therapeutic efficacy [8]. - In preclinical models, this nanorobot demonstrated superior therapeutic effects compared to traditional treatments combining anti-PD-L1 antibodies and oxaliplatin, indicating its significant potential for clinical application in colorectal cancer immunotherapy [10].

Core Viewpoint - The article discusses a novel approach to enhance CD47 blockade therapy for cancer treatment by utilizing biomineralized nanoparticles that facilitate phagocytosis and mitochondrial DNA sensing, leading to improved therapeutic outcomes [2][5]. Group 1: Research Background - Antigen-presenting cells (APCs) mediate the phagocytosis of cancer cells and initiate antigen presentation through sensing mitochondrial DNA (mtDNA), which is a critical mechanism in CD47 blockade therapy [2]. - Current strategies targeting CD47 often lack regulation of mtDNA sensing, limiting their effectiveness [2]. Group 2: Research Findings - The study developed biomineralized nanoparticles ZnCO₃@BSA/siCD47 that enhance CD47 blockade therapy by promoting APC phagocytosis and mtDNA sensing, resulting in significant tumor growth inhibition [2][5]. - The nanoparticles are designed to balance the stable encapsulation of siRNA with efficient intracellular release, achieving effective CD47 silencing and Zn²⁺ overload [5][6]. - In colorectal cancer and melanoma models, ZnCO₃@BSA/siCD47 restored APC function, increased T cell infiltration, and achieved a tumor growth inhibition rate of 93% [5][6]. Group 3: Mechanism of Action - The strategy involves Zn²⁺ overload to enhance phagocytosis and STING activation, while the pH-responsive ZnCO₃@BSA matrix ensures synchronized delivery of Zn²⁺ and siRNA [6]. - The treatment induces CD47 knockdown, calreticulin exposure, and mtDNA release, which are crucial for effective immune response [6].